Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$3.36 USD
-0.16 (-4.55%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.37 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RLAY 3.36 -0.16(-4.55%)
Will RLAY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLAY
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Other News for RLAY
Relay Therapeutics: What's Next For H2 2025?
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights ...
Relay Therapeutics has positive read from Celcuity data, says Barclays
Claire Mazumdar Joins Relay Therapeutics as Director
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News